Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

New Nkarta data backs up natural killer approach to cancer treatment

Valneva eyes first place in chikungunya vaccine race

WHO/PAHO launch free digital health assistant to cut alcohol-related diseases

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

GSK cancer division delivers good news after string of R&D setbacks

toll-like receptor agonist

leonard-schleifer

News/ News/ News/ Oncology/ R&D

Regeneron seeks CheckMate in immuno-oncology play

Phil Taylor CheckMate Pharma, head and neck cancer, immuno-oncology, M&A, melanoma, Oncology, Regeneron, toll-like receptor agonist, vidutolimod 0 Comment

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy

X

Regeneron seeks CheckMate in immuno-oncology play

https://pharmaphorum.com/news/regeneron-seeks-checkmate-in-immuno-oncology-play/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

Frontiers Health Steering Committee spotlight – Monique Levy

Frontiers Health Steering Committee spotlight – Monique Levy

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Most popular

Most Viewed

Elon Musk’s Neuralink brain interface chip set for human trials
Sanofi, Amgen acknowledge Horizon interest as J&J steps back
Amgen to push latecomer obesity drug into midstage testing
GSK cancer division delivers good news after string of R&D setbacks
Novartis' Pluvicto presents survival benefit for castration-resistant prostate cancer

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com